The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
13-Nov-24
Pending
$12.1 billion
Target:
Blue Owl Technology Finance Corp. II (“OTF II”)
Acquiror:
Blue Owl Technology Finance Corp. (“OTF”)
Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF
12-Jul-21
Pending
$1.7 billion
Target:
Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)
Acquiror:
KPS Capital Partners
Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America
16-May-19
$2.0 billion
Target:
Gannett Co., Inc.
Advised Gannett Co., Inc., a media and marketing solutions company, in relation to an unsolicited acquisition proposal from and successful proxy contest with MNG Enterprises, Inc.
02-Nov-16
$NA
Target:
IAC/InterActiveCorp
Advised the Special Committee of the Board of Directors of IAC/InterActiveCorp, a leading media and internet company, on the potential creation of a new class of non-voting common stock
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
16-Mar-16
$942 million
Target:
Rofin-Sinar Technologies, Inc.
Acquiror:
Coherent, Inc.
Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers
11-Dec-12
$862 million
Target:
TNS, Inc.
Acquiror:
Siris Capital Group
Advised the Special Committee of the Board of Directors of TNS, Inc., a leading global provider of data communications and interoperability solutions, on its sale to Siris Capital Group, a private equity firm focused on complex, control equity investments in the telecom, technology and technology-enabled business service sectors
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
07-Feb-11
$548 million
Target:
Wesco Financial Corporation
Acquiror:
Berkshire Hathaway Inc.
Advised the Special Committee of Wesco Financial Corporation in connection with Berkshire Hathaway Inc.'s proposal to acquire the remaining 19.9% of the shares of Wesco’s common stock that it does not presently own
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
02-Dec-10
$NA
Target:
IAC / InterActiveCorp.
Advised the Special Committee of the Board of Directors of IAC, a leading Internet company, on the repurchase of all IAC shares owned by Liberty Media in exchange for a combination of cash and two operating businesses, Evite and Gifts.com
31-Mar-10
$3.3 billion
Target:
EMOBILE Ltd.
Acquiror:
eAccess Ltd.
Advised the Independent Committee of eAccess Ltd., Japan's largest DSL wholesaler, on its business combination through a share exchange with EMOBILE, Ltd., the leading mobile data communications provider in Japan
25-Feb-10
$14.4 billion
Target:
Coca-Cola Enterprises Inc.
Acquiror:
The Coca-Cola Company
Advised the Affiliated Transaction Committee of Coca-Cola Enterprises Inc. on the sale of its North American bottling operations to The Coca-Cola Company and on its concurrent acquisition of The Coca-Cola Company’s bottling operations in the Nordic region
10-Aug-09
$596 million
Target:
Barnes & Noble College Booksellers, Inc.
Acquiror:
Barnes & Noble, Inc.
Advised the Special Committee of the Board of Directors of Barnes & Noble, Inc., the world’s largest bookseller, on its acquisition of Barnes & Noble College Booksellers, Inc.
23-Apr-08
$2.8 billion
Target:
Wendy's International, Inc.
Acquiror:
Triarc Companies, Inc.
Advised the special committee of the board of directors in connection with its merger with Triarc Companies, Inc., the operator of the Arby’s franchise. The combined systems will have approximately 10,000 restaurant units and pro forma annual system sales of approximately $12.5 billion, positioning it as the nation’s third largest quick service restaurant company
30-Jun-07
$52.0 billion
Target:
BCE Inc.
Acquiror:
Teacher's Private Capital, Providence Equity Partners Inc. and Madison Dearborn Partners, LLC
Advised the Board of BCE on a review of a range of strategic alternatives that culminated in an agreement to sell to a consortium consisting of Teacher's Private Capital, Providence Equity Partners and Madison Dearborn Partners for $52.0 billion that was ultimately terminated
30-Mar-07
$24.4 billion
Target:
Alliance Boots plc
Acquiror:
Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina
Advised Alliance Boots plc, the leading international pharmacy-led health and beauty group, on a proposal regarding an offer for the company from a consortium comprising of Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina
25-Jan-07
$3.3 billion
Target:
Cardinal Health, Inc., Pharmaceutical Technologies and Services division
Acquiror:
The Blackstone Group
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
03-Apr-06
$3.7 billion
Target:
Verizon Communications Inc.
Acquiror:
América Móvil and Telmex
(various assets)
Provided independent valuation services in connection with the acquisition by América Móvil and Telmex of a 100% stake in Verizon Dominicana, an approximate 52% stake in Telecomunicaciones de Puerto Rico and an approximate 28.5% stake in Compania Anónima Nacional Teléfonos de Venezuela
09-Sep-05
$1.0 billion
Target:
7-Eleven, Inc.
Acquiror:
Seven-Eleven Japan Co., Ltd
Advised the special committee of 7-Eleven, Inc. in connection with its evaluation of an unsolicited tender offer commenced by Seven-Eleven Japan Co., Ltd
18-Mar-03
$7.0 billion
Target:
Wella AG
Acquiror:
The Procter & Gamble Company
Advised Wella AG, a global market leader in hair care and fragrances, on its sale to The Procter & Gamble Company
27-Mar-02
$168 million
Target:
Morton’s Restaurant Group Inc.
Acquiror:
Castle Harlan, Inc.
Advised the Special Committee of Morton’s on sale of the Company.